“Anti-CD20 antibodies have demonstrated the ability to kill B lymphocytes in animal models and cause malignant cell lysis by activating complement- and antibody-dependent cellular toxicity (ADCC ...

IDEC Pharmaceuticals’s initial customized approach was circumvented by the work to develop anti-CD20 antibodies ... a method for humanizing the antibodies. The magic moment was a breakthrough in the ...

“That's very distinct from all other CD20 antibodies,” he says ... gaining approval in Europe for its recombinant version of human antithrombin, an anti-coagulant secreted in the milk of ...